Core Viewpoint - Speculation regarding a potential acquisition of ABIVAX by Eli Lilly has led to significant share price movements, despite the company's CEO dismissing these rumors as unfounded noise [1][2][3]. Group 1: Share Price Movement - ABIVAX shares experienced a dramatic increase of over 2,000% from July to December 2025, peaking at $145 on December 24 before settling at $118 after the French government dismissed the acquisition rumors [2]. Group 2: Company Clarifications - ABIVAX's CEO, Marc De Garidel, stated that no formal discussions regarding a takeover have occurred and emphasized that any informal conversations do not comply with regulatory requirements [1][3]. - De Garidel highlighted that a public deal announcement would precede any engagement from foreign investment oversight, indicating a structured approach to potential investments [3]. Group 3: Company Focus and Financial Needs - The company is advancing its therapeutic program, obefazimod, which is well-funded through Q4 2027, but still requires additional financing as indicated by discussions with potential investors at the JPMorgan Healthcare conference [3]. - ABIVAX develops antiviral and vaccine products targeting various diseases, including chronic hepatitis B, Ebola, dengue, and ulcerative colitis, as well as commercial vaccines for typhoid, meningococcal, and leptospirosis [4].